Overview

* ORIC Pharmaceuticals ( ORIC ) reports Q3 net loss of $32.6 mln, with decreased operating expenses

* Cash and investments of $413 mln expected to fund operations into 2H 2028

Outlook

* Company anticipates cash to fund operations into 2H 2028

Result Drivers

* LEADERSHIP APPOINTMENT - Appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to support late-stage development

* Research and development (R&D) expenses were $28.8 million for the three months ended September 30, 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$32.59

Income mln

Q3 -$36.67

Income mln

from

Operatio

ns

Q3 $36.67

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Oric Pharmaceuticals Inc ( ORIC ) is $19.50, about 36% above its November 12 closing price of $12.48

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)